<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): DECEMBER 13, 2000
ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 0-21198 76-0233274
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
</TABLE>
2408 TIMBERLOCH PLACE, SUITE B-4
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 719-3400
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
<PAGE> 2
ITEM 5. OTHER EVENTS
On December 13, 2000, Zonagen, Inc. issued a press release announcing
that it has entered into an Option Agreement with Wyeth-Ayerst Laboratories, the
pharmaceutical division of American Home Products Corporation ("Wyeth"), to
collaborate in the development of a human immunocontraceptive vaccine. The
collaborative Proof of Concept Study (the "Study") will evaluate the effects of
the immunocontraceptive vaccine in baboons over an 18-month period. Wyeth will
contribute to the study with both funding and manpower. The outside costs of the
study are not expected to exceed $200,000. The Option Agreement contains the
major provisions required to complete a license agreement. Upon the exercise of
the option, Wyeth would obtain exclusive worldwide rights to the zona pellucida
contraceptive technology. The option may be exercised at any time during the
Study or for a designated period thereafter. In the event that a license
agreement is entered into, Wyeth will bear all costs associated with the
clinical development and marketing of the product and could pay milestones
totaling up to $22.5 million plus royalties on product sales if the product is
ultimately approved.
The press release is filed as an exhibit to this Current Report on Form
8-K and is incorporated by reference herein.
ITEM 7. EXHIBITS
Exhibit 99.1 -- Press Release dated December 13, 2000.
2
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZONAGEN, INC.
Date: December 13, 2000
By: /s/ Louis Ploth, Jr.
------------------------------------
Louis Ploth, Jr.
Vice President, Finance
3
<PAGE> 4
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------ -----------
99.1 Press Release dated December 13, 2000.
